Buy Rating Reaffirmed as Gain Therapeutics Advances Rexaceract Toward Phase 2; $7 Price Target Unchanged
at www.tipranks.com (Wed, 11-Nov 3:35 PM)
BTIG Maintains Buy Rating and $5 Price Target on Rexaceract as Early Data Suggest Slowed Parkinson’s Progression
at www.tipranks.com (Wed, 11-Nov 5:26 AM)
Gain Therapeutics GAAP EPS of -$0.07 beats by $0.05
at seekingalpha.com (Tue, 10-Nov 9:06 AM)
